TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32698121
Drug: Higher protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher protein diet (2.50 g·kg‐1·day‐1)
Study: 32698121
Drug: Moderate protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate protein diet (1.25 g·kg‐1·day‐1)
Study: 38049713
Drug: Conventional fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fluid therapy
Study: 33075806
Drug: Dapagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (10 mg) added to verinurad (9 mg) and febuxostat (80 mg)
Study: 33075806
Drug: Placebo added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo added to verinurad (9 mg) and febuxostat (80 mg)
Study: 32063089
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplement (LNS) provided to women during gestation and the first 6 months postpartum and to their infants from age 6 to 18 months.
Study: 39221611
Drug: Monthly fremanezumab
Normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monthly fremanezumab
Study: 32246762
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone (400 mg pessary) once daily until 37 weeks
Study: 33599345
Drug: Crocin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crocin (15 mg)
Study: 33148013
Drug: Edoxaban 60
Normalized name: edoxaban 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 60 mg (30 mg dose-reduced)
Study: 33992536
Drug: Intravenous autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous autologous bone marrow-derived mesenchymal stromal cells (BMMSCs) at a dosage of 2 million cells per kilogram of body weight
Study: 34433601
Drug: Multidisciplinary group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary group programme (Energetic) consisting of a 4 months intervention with weekly meetings covering four modules: aerobic exercise training, education about aerobic exercise, self-management training, and implementation and relapse prevention.
Study: 34433601
Drug: Suggestions for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suggestions for programme improvement include a combination of face to face and e-health, enhancement of therapists' skills, and inclusion of more booster sessions.
Study: 35242206
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with rehabilitation therapy
Study: 33110649
Drug: Topical salicylic
Normalized name: salicylic acid Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical salicylic acid (SA)
Study: 36347387
Drug: MSC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSC therapy (infused at weeks 6 and 7 after transplantation, tacrolimus withdrawn at week 8)
Study: 35289144
Drug: Conventional-dose CT
Normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose CT
Study: 39706874
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus rosiglitazone
Study: 32820132
Drug: Combined strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined strength and power training (twice a week for 8 weeks)
Study: 32324130
Drug: NAPSO 220
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAPSO 220 mg
Study: 32324130
Drug: NAPSO 440
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAPSO 440 mg
Study: 32324130
Drug: NAPSO 550
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAPSO 550 mg
Study: 32324130
Drug: NAP 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAP 500 mg
Study: 32324130
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of NAPSO
Study: 32324130
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses of NAPSO (220 mg, 440 mg)
Study: 34358343
Drug: Dupilumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab (300 mg) every 2 weeks for 16 weeks
Study: 32078391
Drug: Pembrolizumab 2
Normalized name: pembrolizumab 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 2 mg/kg or 10 mg/kg every 3 weeks (up to 35 cycles/2 years)
Study: 32078391
Drug: Pembrolizumab (second-course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (second-course treatment)
Study: 32078391
Drug: Pembrolizumab (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (after completing treatment)
Study: 36598543
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg CBD
Study: 35583161
Drug: Prowel® (synbiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prowel® (synbiotic drug)
Study: 34751654
Drug: Printed brochure
Normalized name: norgestimate
DrugBank: Norgestimate (DB00957)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Printed brochure on nutrition guidelines in addition to usual care for HIV treatment
Study: 32859145
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 mg/kg dextrose)
Study: 32459016
Drug: Topical 6%
Normalized name: menthol topical 6% topical spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 6% gabapentin
Study: 32459016
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (plain permeation cream)
Study: 33140403
Drug: MDZ‐NS 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDZ‐NS 5 mg
Study: 35179756
Drug: Pharmacological Treatment
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological Treatment (PT)
Study: 35314634
Drug: Belinostat (500-750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belinostat (500-750 mg/m2 1×/day × 5 days every three weeks)
Study: 35314634
Drug: Control (standard-of-care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard-of-care therapy including temozolomide and radiation therapy)
Study: 34715827
Drug: Antifungal therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antifungal therapy after surgery
Study: 34715827
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antifungal therapy)
Study: 33813637
Drug: Antifungal therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antifungal therapy
Study: 34004271
Drug: Synthetic antibiotic
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic antibiotic (ATB)
Study: 32447657
Drug: Anti-PD-1/PD-L1 monoclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1/PD-L1 monoclonal antibodies
Study: 32447657
Drug: Combination immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination immunotherapy
Study: 32693660
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) along with pharmacotherapy (PT)
Study: 32693660
Drug: Pharmacotherapy (PT)
Normalized name: PT-2385
DrugBank: PT-2385 (DB16055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy (PT) only
Study: 32434001
Drug: Prepregnancy platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prepregnancy platelet factor 4 (third tertile vs first tertile) in aspirin group
Study: 32860399
Drug: 4000 mg
Normalized name: talc 4000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4000 mg CLA per day
Study: 32860399
Drug: 2000 IU
Normalized name: D 2000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 IU vitamin D-3 and 4000 mg CLA per day
Study: 35593607
Drug: Nimesulide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide (100 mg) + Thiocolchicoside (8 mg)
Study: 34498818
Drug: 0.6 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 g/kg of carbohydrate (CHO)
Study: 34498818
Drug: 0.6 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 g/kg of carbohydrate with 6 mg/kg of caffeine (CAF+CHO)
Study: 35229960
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg nicotine delivered over 1 min
Study: 35229960
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg nicotine delivered over 2.5 min
Study: 35229960
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg nicotine delivered over 5 min
Study: 35229960
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg nicotine delivered over 10 min
Study: 35229960
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg nicotine/min
Study: 35229960
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg nicotine/min
Study: 35229960
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg nicotine/min
Study: 35229960
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg nicotine/min
Study: 35785593
Drug: Daily teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daily teriparatide
Study: 35785593
Drug: Weekly high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly high-dose teriparatide
Study: 35027397
Drug: Vector vaccine
Normalized name: COVID-19 non-replicating viral vector vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vector vaccine ChAdOx1 nCoV-19 (Oxford-AstraZeneca)
Study: 35027397
Drug: mRNA vaccine
Normalized name: RSV mRNA vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA vaccine (homologous)
Study: 34928302
Drug: Vector vaccine
Normalized name: COVID-19 non-replicating viral vector vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vector vaccine
Study: 39749328
Drug: mRNA vaccine
Normalized name: RSV mRNA vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA vaccine
Study: 32866440
Drug: Tocilizumab 162
Normalized name: TOCILIZUMAB 162MG/0.9ML AUTOINJECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab 162 mg subcutaneously weekly for 48 weeks
Study: 36598543
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg CBD
Study: 35851700
Drug: Oral food
Normalized name: Nutritional Supplement Oral Food, Solid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral food challenges
Study: 34393202
Drug: Analgesic treatment
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic treatment
Study: 33802012
Drug: HMB complex
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMB complex (2.4 g of HMB + 14 g of glutamine + 14 g of arginine)
Study: 33802012
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (glutamine complex, 7.2 g of protein including 6 g of glutamine)
Study: 37650921
Drug: Curcumin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (1 g) with piperine (5 mg) twice daily
Study: 32235946
Drug: Cawthorne‐Cooksey exercises
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cawthorne‐Cooksey exercises and simple balance exercises (15 min, twice a day, unsupervised)
Study: 33866270
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: TV 6 ml/kg, PEEP 5 cmH20
Study: 33866270
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: TV 6 ml/kg, PEEP 8 cmH20
Study: 33866270
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: TV 8 ml/kg, PEEP 5 cmH20
Study: 33866270
Drug: Group D:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group D: TV 8 ml/kg, PEEP 8 cmH20
Study: 33949001
Drug: r‐ATG 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐ATG 2.5 mg/kg
Study: 33949001
Drug: r‐ATG 3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐ATG 3.5 mg/kg
Study: 33284903
Drug: Phosphate-buffered saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate-buffered saline solution (negative control)
Study: 36412376
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy for 30 min, 3 days/week for 4 weeks
Study: 32008198
Drug: Resistant starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistant starch (RS) supplementation (16 g RS/day)
Study: 35948873
Drug: REACH intervention
Normalized name: beach strawberry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: REACH intervention (text message‐delivered self‐management support focusing on medication adherence, diet, and exercise)
Study: 33276298
Drug: Prophylactic antibiotic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotic use in neonatal lambs
Study: 32151119
Drug: Oral/enteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral/enteral nutrition plus pantoprazole
Study: 32151119
Drug: Oral/enteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral/enteral nutrition only
Study: 35460853
Drug: Anesthesia administered
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthesia administered
Study: 32522414
Drug: 0.1‐mL ID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1‐mL ID injection of purified Vero cell rabies vaccine (PVRV) on days 0 and 28
Study: 32522414
Drug: 0.5‐mL intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5‐mL intramuscular PVRV on D0, D7 and D28
Study: 36184275
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) infusion following hysteroscopic adhesiolysis
Study: 33028555
Drug: Varenicline and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline and nicotine replacement therapy (NRT) lozenges
Study: 33028555
Drug: Varenicline and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline and placebo lozenges
Study: 34135056
Drug: Intraoperative wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative wound irrigation with aqueous 10% povidone–iodine solution (40 mL for 1 min before skin suture)
Study: 34135056
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (100 mL for 1 min before skin suture)
Study: 32134735
Drug: Zinc deficiency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc deficiency defined as serum zinc level < 75 μg/dL
Study: 32081593
Drug: Low Intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Intensity Laser Therapy (LILT) applied on the experimental side on the 1st, 3rd, 5th, 7th, 14th and 15th days consecutively.
Study: 32081593
Drug: Low Intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Intensity Laser Therapy (LILT) at the end of canine retraction (4.5 months).
Study: 36247106
Drug: Weekly group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly group singing for 12 weeks
Study: 35012462
Drug: Transdermal glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal glyceryl trinitrate (GTN) 5 mg daily for 4 days
Study: 32998005
Drug: β-blockers (high-dose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-blockers (high-dose, medium-dose, low-dose)
Study: 32998005
Drug: Medium-dose β-blockers
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose β-blockers
Study: 32998005
Drug: Vasodilating β-blockers
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vasodilating β-blockers
Study: 32740976
Drug: Experimental attention
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Experimental attention remediation treatment
Study: 35331535
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea infusion with standardized breakfast
Study: 32696033
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of benzathine penicillin G
Study: 32696033
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of benzathine penicillin G
Study: 34081196
Drug: Direct Oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct Oral Anticoagulants (DOAC) treatment prior to lockdown
Study: 34081196
Drug: Direct Oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct Oral Anticoagulants (DOAC) treatment during lockdown
Study: 34902081
Drug: Trichoderma asperellum
Normalized name: Trichoderma harzianum
DrugBank: Trichoderma harzianum (DB10703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trichoderma asperellum (quality and organic seed-treatment products)
Study: 33947295
Drug: Risankizumab 150
Normalized name: RISANKIZUMAB 150MG/ML ON-BODY KIT 2.4ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risankizumab 150 mg/mL administered via prefilled syringe (PFS)
Study: 33947295
Drug: Risankizumab 150
Normalized name: RISANKIZUMAB 150MG/ML ON-BODY KIT 2.4ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risankizumab 150 mg/mL administered via autoinjector (AI)
Study: 36574828
Drug: Ibuprofen (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (600 mg)
Study: 35955123
Drug: Cognitive‐behavioral smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavioral smoking cessation treatment along with an App with active therapeutic components (SinHumo App)
Study: 35955123
Drug: Cognitive‐behavioral treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavioral treatment along with the use of a control App (without active components)
Study: 37833472
Drug: Hydromorphone 2
Normalized name: HYDROmorphone 2 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone 2 mg
Study: 36263927
Drug: Fosnetupitant 235
Normalized name: fosnetupitant 235 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosnetupitant 235 mg infusion
Study: 36263927
Drug: Fosnetupitant (17.6–353
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosnetupitant (17.6–353 mg) infusion
Study: 32504593
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy plus LDFRT (0.5 Gy twice daily for 2 days)
Study: 32504593
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy alone
Study: 35755061
Drug: Height-based dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Height-based dosing algorithm of bupivacaine
Study: 35755061
Drug: Constant dose
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant dose of bupivacaine (Conventional group)
Study: 34655135
Drug: FITOPROT (mucoadhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: FITOPROT (mucoadhesive phytomedication containing curcuminoids and Bidens pilosa L.)
Study: 32352644
Drug: Dapagliflozin up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin up to 10 mg once daily
Study: 34251414
Drug: Cytarabine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytarabine (100 mg/m2 per day on days 4-10) and Daunorubicin (60 mg/m2 per day on days 4-6) followed by Cytarabine consolidation (2000 mg/m2 per day on days 4-8) with G3139 (7 mg/m2 per day on days 1-10 for induction or days 1-8 for consolidation)
Study: 34251414
Drug: Cytarabine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytarabine (100 mg/m2 per day on days 4-10) and Daunorubicin (60 mg/m2 per day on days 4-6) followed by Cytarabine consolidation (2000 mg/m2 per day on days 4-8) without G3139
Study: 34251414
Drug: Cytarabine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytarabine (100 mg/m2 per day on days 4-10) and Daunorubicin (60 mg/m2 per day on days 4-6) followed by Cytarabine consolidation (2000 mg/m2 per day on days 4-8) with G3139
Study: 34664868
Drug: Carbohydrate group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate group (400 mL carbohydrate drink 2 hours before surgery)
Study: 35112455
Drug: Relaxing the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxing the UACR criterion from 300 mg/g to 210 mg/g
Study: 33820541
Drug: Warming blanket
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warming blanket and infusion thermometer
Study: 32320566
Drug: Ruxolitinib (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib (10 mg twice daily)
Study: 33861741
Drug: Oral ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ivermectin (directly observed treatment)
Study: 33861741
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (referral for topical treatment)
Study: 34388395
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (800 μg twice daily for 14 days)
Study: 32962674
Drug: SIB-IMRT (60.62
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIB-IMRT (60.62 Gy equivalent dose in 2-Gy fractions)
Study: 32962674
Drug: SIB-IMRT +
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIB-IMRT + concurrent chemotherapy (weekly paclitaxel and a platinum-based drug for 5-6 weeks)
Study: 32962674
Drug: SIB-IMRT +
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIB-IMRT + concurrent chemotherapy
Study: 32841739
Drug: Buccal Micronucleus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal Micronucleus Cytome Assay (BMCyt)
Study: 36220069
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of TRE and LCD
Study: 32819394
Drug: Home-based contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based contraceptive delivery (condoms, pills, injection, implant) during the routine 40-day postpartum visit.